Sarepta Provides New Elevidys Safety Data, Reveals Zero Ambulatory Deaths

By /

Jefferies analysts said these detailed safety outcomes confirm the gene therapy’s positive risk/benefit profile in ambulatory patients with Duchenne muscular dystrophy.

Scroll to Top